CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

eletriptan

Trade name: relpax

Small moleculeapproved

Approved

Dec 26, 2002

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan. — NCATS

Clinical trial activity

15 trials · 7 clinical orgs · 15 marketing orgs

Phase 1
2
Phase 2
7
Phase 3
6
Phase 4
4

Earliest trial started Jul 1, 1996 (NCT01978496)

Timeline

1990s

  1. Jan 1, 1996

    Pfizer — Earliest Phase 3 Sponsor(trial)

2000s

  1. Dec 26, 2002

    Pfizer — Earliest FDA Approval

  2. Dec 26, 2002

    Pfizer — NDA Organization

  3. Dec 26, 2002

    Upjohn — Marketing Organization

  4. Dec 26, 2002

    Pharmacia — NDA Secondary Org

  5. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  6. Jan 1, 2009

    Pfizer — Earliest Phase 1 Sponsor(trial)

2010s

  1. Jul 29, 2013

    Apotex — Marketing Organization

  2. Jun 16, 2017

    Zydus Discovery DMCC — Marketing Organization

  3. Jun 27, 2017

    Teva — Marketing Organization

  4. Aug 11, 2017

    Mylan — Marketing Organization

  5. Aug 29, 2017

    Ajanta Pharma Ltd — Marketing Organization

  6. Aug 29, 2017

    Chartwell Pharmaceuticals — Marketing Organization

  7. May 25, 2018

    Amneal Pharmaceuticals — Marketing Organization

  8. May 25, 2018

    Jerome Stevens Pharmaceuticals — Marketing Organization

  9. Jan 15, 2019

    Aurobindo Pharma — Marketing Organization

2020s

  1. Jul 13, 2020

    Yung Shin Pharm. Ind. Co., Ltd. — Marketing Organization

  2. Jul 13, 2022

    Beximco — Marketing Organization

  3. Jul 7, 2025

    Annora Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 26, 2002

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12
Mol. weight
382.53 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole hydrobromide
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan
  • eletriptan hydrobromide
  • eletriptan hydrobromide
  • eletriptan hydrobromide
  • eletriptan hydrobromide
  • eletriptan hydrobromide
  • eletriptanum
  • eletriptanum
  • (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole
  • (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole monohydrobromide
  • relpax
  • relpax
  • relpax
  • relpax
  • relpax
  • uk-116044
  • uk-116044
  • uk-116,044
  • uk 116044-04
  • uk-11604404
  • uk-11604404
  • uk-116,044-04
  • uk-116044-04
  • uk-116044-04
  • uk-116044-04
  • uk-116044-04 [as hydrobromide)
  • uk-116044-04 [as hydrobromide)
  • uk 166044
  • uk 166,044
  • uk-166044
  • uk-166,044

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01619176N/AOct 1, 2012Chinese Academy of Medical Sciences, Jiao Tong University
NCT01139515Phase 1Jul 1, 2010Pfizer
NCT00871806Phase 1Apr 1, 2009Pfizer
NCT00751803Phase 2Aug 1, 2008Boehringer Ingelheim
NCT01276977N/AApr 1, 2008California Medical Clinic for Headache
NCT00385008Phase 3Sep 1, 2006GlaxoSmithKline
NCT00174395Phase 4Mar 1, 2005Pfizer
NCT00259649Phase 4Aug 1, 2004Pfizer, University of Pittsburgh
NCT00632385Phase 4Jan 1, 2003Pfizer
NCT00634985Phase 4Nov 1, 2002Pfizer
NCT01859481Phase 3Mar 1, 2000Pfizer
NCT01989936Phase 3Jan 1, 1999Pfizer
NCT01986270Phase 3Dec 1, 1996Pfizer
NCT01986088Phase 3Nov 1, 1996Pfizer
NCT01978496Phase 3Jul 1, 1996Pfizer
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit111031996
Boehringer IngelheimFor profit1112008
California Medical Clinic for HeadacheAcademic/Hospital1112008
Chinese Academy of Medical SciencesAcademic/Hospital1112012
GlaxoSmithKlineFor profit1112006
Jiao Tong UniversityAcademic/Hospital1012012
University of PittsburghAcademic/Hospital1112004
7 organizations
Page 1 / 1

Marketing (18)

OrganizationOrg typeRelationshipDate
Ajanta Pharma LtdFor profitMKTGAug 29, 2017
Amneal PharmaceuticalsFor profitMKTGMay 25, 2018
Annora PharmaFor profitMKTGJul 7, 2025
ApotexFor profitMKTGJul 29, 2013
Aurobindo PharmaFor profitSYNJan 15, 2019
Aurobindo PharmaFor profitMKTGJan 15, 2019
BeximcoFor profitMKTGJul 13, 2022
Chartwell PharmaceuticalsFor profitMKTGAug 29, 2017
Jerome Stevens PharmaceuticalsFor profitMKTGMay 25, 2018
MylanFor profitMKTGAug 11, 2017
MylanFor profitSYNAug 11, 2017
PfizerFor profitSYNDec 26, 2002
PfizerFor profitNDADec 26, 2002
PharmaciaFor profitNDA2Dec 26, 2002
TevaFor profitMKTGJun 27, 2017
UpjohnFor profitMKTGDec 26, 2002
Yung Shin Pharm. Ind. Co., Ltd.For profitMKTGJul 13, 2020
Zydus Discovery DMCCFor profitMKTGJun 16, 2017